新版医保药品目录落地月余 99种新药已进驻超万家定点机构

Core Viewpoint - The new medical insurance drug list has been implemented nationwide since January 1, 2023, with 99 new drugs already available in over 12,000 designated medical institutions, aiming to improve patient access to essential medications [1][5]. Group 1: Implementation and Accessibility - The new drug list has led to the addition of over 30 new drugs at the People's Hospital of Jinxing County, ensuring that patients can access and afford these medications [1][3]. - In Sichuan, a dual-channel supply system has been established for essential new drugs, allowing for direct reimbursement from the insurance fund, which alleviates the financial burden on hospitals [5][6]. - The price of a previously expensive drug for coronary heart disease has been reduced from 9,988 yuan to 2,790 yuan per injection, significantly lowering out-of-pocket costs for patients [6]. Group 2: Challenges in Implementation - Despite the progress, there are still bottlenecks in the availability of "nationally negotiated drugs" in hospitals, primarily due to the rapid increase in the number of new drugs compared to the limited capacity of hospital formularies [9][11]. - Hospitals face challenges in deciding which new drugs to adopt, especially when multiple similar treatments are available, complicating the procurement process [12][15]. - The approval process for new drugs can take from one to twelve months, which delays their availability in hospitals [12][13]. Group 3: Commercial Health Insurance - A new commercial health insurance innovation drug list has been introduced alongside the medical insurance drug list, including 19 innovative drugs that are not covered by basic insurance [18][22]. - A case study highlights a patient with diffuse large B-cell lymphoma who benefited from a CAR-T therapy covered by commercial insurance, demonstrating the financial relief provided by such policies [20][22]. - The commercial insurance aims to address the diverse medication needs of patients, focusing on innovative and advanced treatments, while basic insurance maintains a focus on essential coverage [22].